GCTK Stock Price, GlucoTrack, Inc. Quote, Chart

Market Summary

USD0.51+0.02

Delayedas of 17 May 2024, 12:37 pm

4.08%

GCTK Alerts

1 major insider buys recently.

GCTK Stock Price

View Fullscreen

GCTK RSI Chart

GCTK Valuation

Market Cap

13.4M

Price/Earnings (Trailing)

-1.54

Price/Sales (Trailing)

65.85

Price/Free Cashflow

-1.64

GCTK Price/Sales (Trailing)

GCTK Profitability

Return on Equity

-2.3K%

Return on Assets

-414.91%

Free Cashflow Yield

-60.99%

GCTK Fundamentals

GCTK Revenue

Revenue (TTM)

208.0K

GCTK Earnings

Earnings (TTM)

-8.7M

Earnings Growth (Yr)

-127.6%

Earnings Growth (Qtr)

-21.35%

Breaking Down GCTK Revenue

52 Week Range

0.52

(Low)(High)

Last 7 days

-12.5%

Last 30 days

-5.8%

Last 90 days

104.2%

Trailing 12 Months

6.5%

How does GCTK drawdown profile look like?

GCTK Financial Health

Current Ratio

1.31

GCTK Investor Care

Shares Dilution (1Y)

31.12%

Diluted EPS (TTM)

0.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	0
2019	40.8K	136.1K	140.3K	208.0K
2018	562.5K	486.9K	466.0K	43.5K
2017	618.8K	327.9K	337.5K	630.5K
2016	156.5K	470.9K	482.2K	611.7K
2015	80.6K	101.5K	122.3K	143.2K
2014	0	0	0	59.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of GlucoTrack, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	sycoff drew	bought	230,000	1.26	182,540	-

Which funds bought or sold GCTK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	reduced	-43.79	-2,978	7,268	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-3,484	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	added	43.3	91,347,000	203,506,000	0.12%
May 15, 2024	Virtue Capital Management, LLC	new	-	12,600	12,600	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	4,000	4,000	-%
May 13, 2024	UBS Group AG	sold off	-100	-1,258	-	-%
May 13, 2024	ALERUS FINANCIAL NA	unchanged	-	4,822	22,938	-%
May 10, 2024	BOSTON FINANCIAL MANGEMENT LLC	sold off	-100	-6,897	-	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	4,516	4,516	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling GCTK?

Are funds buying GCTK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GCTK

No. of Funds

GCTK Alerts

1 major insider buys recently.

Unveiling GlucoTrack, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 03, 2024	sabby management, llc	9.99%	2,087,130	SC 13G

Recent SEC filings of GlucoTrack, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 08, 2024	D	D
May 02, 2024	8-K	Current Report
Apr 24, 2024	4	Insider Trading
Apr 24, 2024	3	Insider Trading
Apr 01, 2024	DEF 14A	DEF 14A
Mar 28, 2024	10-K	Annual Report
Mar 22, 2024	PRE 14A	PRE 14A

Peers (Alternatives to GlucoTrack, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.4B	40.3B	-3.99%	-3.65%	32.43	4.52	-2.84%	-3.08%
BDX	68.4B	19.7B	2.45%	-5.81%	51.31	3.47	4.82%	-17.56%
ALGN	20.6B	3.9B	-10.40%	-6.17%	44.52	5.25	5.72%	46.72%
BAX	17.9B	14.9B	-11.17%	-17.84%	6.76	1.2	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.5B	12.5B	4.37%	-2.87%	24.53	0.76	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.13	3.23	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-63	1.5	0.23%	91.03%
AXNX	3.5B	387.1M	0.46%	29.28%	-216.68	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.88	0.4	7.94%	-1661.78%
ANIK	378.1M	169.3M	-	-1.96%	-4.92	2.23	7.49%	-244.90%
ANGO	257.2M	324.0M	-1.38%	-32.77%	-1.34	0.79	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

GlucoTrack, Inc. News

Latest updates

GlucoTrack, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3
Revenue	-	-	-	-	68.00	4.00	111	26.00	-	-	15.00	28.00	423	21.00	91.00	96.00	130	11.00	382	89.00	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	3,143	2,669	2,657	2,696	1,451	1,498	1,965	1,354	1,555	1,123
Operating Expenses	45.2%	887	611	756	674	985	1,005	1,051	1,011	1,611	2,022	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	3.3%	93.00	90.00	91.00	128	168	151	125	235	265	283	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	25.6%	476	379	413	402	377	401	425	1,214	534	692	-	-	-	-	-	-	-	-	-	-	-
Net Income	11.3%	-509	-574	-734	6,433	-996	-898	-1,021	-3,180	-1,572	-1,962	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-57.1%	2,106	4,905	7,195	8,982	1,251	2,438	3,511	4,317	5,359	6,265	7,633	8,607	9,628	10,606	11,473	12,213	13,333	1,096	1,974	3,055	839
Current Assets	-60.2%	1,937	4,868	7,169	8,945	1,206	2,379	3,428	4,224	5,231	6,105	7,419	8,312	9,280	10,229	11,114	11,917	12,815	718	1,440	2,506	262
Cash Equivalents	-66.7%	1,497	4,492	6,888	8,774	1,003	2,312	3,241	3,898	4,839	6,113	7,078	7,970	8,953	9,885	10,764	11,570	12,478	476	1,279	2,332	85.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	288	285	279	284	281	253	225	184	139	130	157
Net PPE	203.7%	82.00	27.00	17.00	27.00	35.00	40.00	44.00	49.00	60.00	69.00	71.00	117	133	149	148	125	133	134	145	141	147
Liabilities	1.3%	1,730	1,708	1,638	1,239	1,240	1,208	1,156	1,127	1,128	1,110	1,132	1,321	1,479	1,624	1,526	1,791	2,386	2,508	2,836	3,040	3,525
Current Liabilities	-2.0%	1,482	1,512	1,454	1,050	1,047	1,013	965	935	916	883	898	1,085	1,248	1,345	1,319	1,573	1,984	2,272	2,440	2,628	3,096
Shareholder's Equity	-88.2%	376	3,197	5,557	7,743	11.00	1,230	2,355	3,190	4,231	5,155	6,501	7,286	8,149	8,982	9,946	10,422	10,947	-	-	15.00	-
Retained Earnings	-2.7%	-112,780	-109,853	-107,441	-105,218	-103,187	-101,901	-100,614	-99,686	-98,559	-97,466	-95,960	-95,156	-94,303	-93,399	-92,519	-92,010	-91,436	-90,703	-90,104	-89,107	-88,208
Additional Paid-In Capital	0.1%	113,029	112,966	112,944	112,918	103,156	103,095	102,906	102,821	102,763	102,612	102,417	102,223	102,214	102,351	102,118	102,053	101,978	89,005	88,945	88,823	85,245
Shares Outstanding	28.1%	26,756	20,892	20,892	20,892	15,504	15,501	15,474	15,474	15,462	15,470	15,449	-	15,444,697	-	14,947,139	15,425,005	-	-	-	-	-
Float	-	-	-	-	5,363	-	-	-	3,930	-	-	-	32,694	-	-	-	48,840	-	-	-	48,584	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-22.0%	-2,942	-2,411	-1,880	-954	-1,313	-940	-608	-916	-1,265	-973	-894	-969	-933	-844	-765	-903	-989	-796	-1,061	-1,220	-821
Share Based Compensation	4.8%	22.00	21.00	31.00	172	57.00	165	76.00	47.00	151	157	8.00	9.00	49.00	-	9.00	11.00	2.00	-95.77	122	152	179
Cashflow From Investing	-Infinity%	-59.00	-	-	-	-	5.00	-	-	-	-4.00	-	-	-	-7.00	-31.00	-	-15.00	-446*	-12.64	-3.53	-6.38
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,009	-574*	-	3,442	756

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GCTK Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Research and development	$ 2,148	$ 642
General and administrative	733	642
Selling and marketing expenses	70
Total operating expenses	2,951	1,284
Operating loss	2,951	1,284
Finance expenses (income), net	(24)	2
Net Loss	2,927	1,286
Other comprehensive income:
Foreign currency translation adjustment	(6)	(5)
Comprehensive loss for the period	$ 2,921	$ 1,281
Basic net loss per common stock	$ (0.12)	$ (0.08)
Diluted net loss per common stock	$ (0.12)	$ (0.08)
Weighted average number of common stock outstanding used in computing basic net loss per share	24,959,768	15,503,632
Weighted average number of common stock outstanding used in computing diluted net loss per share	24,959,768	15,503,632

GCTK Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 1,497,000	$ 4,492,000
Other current assets	440,000	376,000
Total current assets	1,937,000	4,868,000
Operating lease right-of-use asset, net (Note 3C)	77,000
Property and equipment, net	82,000	27,000
Restricted cash	10,000	10,000
TOTAL ASSETS	2,106,000	4,905,000
Current Liabilities
Accounts payable	1,014,000	839,000
Operating lease liability, current (Note 3C)	24,000
Other current liabilities	444,000	673,000
Total current liabilities	1,482,000	1,512,000
Non-current Liabilities
Loans from stockholders	195,000	196,000
Operating lease liability, non-current (Note 3C)	53,000
Total liabilities	1,730,000	1,708,000
Commitments and contingent liabilities (Note 4)
Stockholders’ Equity
Common Stock of $ 0.001 par value (“Common Stock”): 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 26,756,369 and 20,892,193 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	27,000	20,000
Additional paid-in capital	113,029,000	112,966,000
Receipts on account of shares	78,000	48,000
Accumulated other comprehensive income	22,000	16,000
Accumulated deficit	(112,780,000)	(109,853,000)
Total stockholders’ equity	376,000	3,197,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,106,000	$ 4,905,000

About GlucoTrack, Inc.

GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

WEBSITE	https://glucotrack.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	3

GlucoTrack, Inc. Frequently Asked Questions

What is the ticker symbol for GlucoTrack, Inc.? What does GCTK stand for in stocks?

GCTK is the stock ticker symbol of GlucoTrack, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GlucoTrack, Inc. (GCTK)?

As of Thu May 16 2024, market cap of GlucoTrack, Inc. is 13.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GCTK stock?

You can check GCTK's fair value in chart for subscribers.

What is the fair value of GCTK stock?

You can check GCTK's fair value in chart for subscribers. The fair value of GlucoTrack, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GlucoTrack, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GCTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GlucoTrack, Inc. a good stock to buy?

The fair value guage provides a quick view whether GCTK is over valued or under valued. Whether GlucoTrack, Inc. is cheap or expensive depends on the assumptions which impact GlucoTrack, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GCTK.

What is GlucoTrack, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, GCTK's PE ratio (Price to Earnings) is -1.54 and Price to Sales (PS) ratio is 65.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GCTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on GlucoTrack, Inc.'s stock?

In the past 10 years, GlucoTrack, Inc. has provided -0.408 (multiply by 100 for percentage) rate of return.